Nextech Trims Kymera at a Recent High — think Foolishly before acting.

1 day ago 3

Seena Hassouna, The Motley Fool

Thu, March 19, 2026 astatine 10:57 AM CDT 4 min read

Nextech Invest, Ltd. disclosed successful a February 17, 2026, Securities and Exchange Commission (SEC) filing that it reduced its involvement successful Kymera Therapeutics (NASDAQ:KYMR) by 62,013 shares, an estimated $4.19 cardinal commercialized based connected quarterly mean pricing.

Nextech Invest sold 62,013 shares of Kymera Therapeutics astatine an estimated transaction worth of $4.19 cardinal (based connected quarterly mean pricing).
The quarter-end presumption worth accrued by $2.41 million, reflecting some stock income and terms movement.
The transaction represented 0.4% of fund’s 13F reportable assets nether absorption (AUM).
Post-trade holding: 278,896 shares valued astatine $21.70 cardinal arsenic of December 31, 2025.
The presumption present represents 2.1% of AUM, which places it extracurricular the fund's apical 5 holdings.

According to the SEC filing dated February 17, 2026, Nextech Invest, Ltd. sold 62,013 shares of Kymera Therapeutics successful the 4th quarter. The estimated transaction worth was $4.19 million, calculated utilizing the mean closing terms during the quarter. The quarter-end worth of the presumption accrued by $2.41 million, a fig reflecting some trading enactment and changes successful the stock’s price.

Nextech Invest, Ltd. continued mean trading activity, trimming its Kymera involvement to 2.1% of 13F AUM
Top 5 holdings aft the filing:
- NASDAQ:RVMD: $605.43 cardinal (58.5% of AUM)
- NASDAQ:TYRA: $106.63 cardinal (10.3% of AUM)
- NASDAQ:TNGX: $64.38 cardinal (6.2% of AUM)
- NASDAQ:ORIC: $58.59 cardinal (5.7% of AUM)
- NASDAQ:RLAY: $39.77 cardinal (3.8% of AUM)
As of February 17, 2026, shares of Kymera Therapeutics were priced astatine $84.84, up 128.5% implicit the past year, outperforming the S&P 500 by 118.13 percent points

Metric

Value

Price (as of marketplace adjacent March 18, 2026)	$84.84
Market Capitalization	$6.41 billion
Revenue (TTM)	$39.21 million
Net Income (TTM)	($311.35 million)

Kymera Theraputics develops caller tiny molecule therapeutics that people and degrade disease-causing proteins, with cardinal programs successful immunology, inflammation, hematologic malignancies, and coagulated tumors.
The institution operates a research-driven biopharmaceutical exemplary portion advancing its proprietary objective pipeline.
Kymera serves healthcare providers, probe institutions, and pharmaceutical partners focused connected innovative treatments for superior diseases.

Kymera Therapeutics develops targeted macromolecule degradation therapies for immunology and oncology, advancing a diversified objective pipeline. The company’s strategy centers connected first-in-class therapies for diseases with precocious unmet aesculapian need, leveraging a robust probe level to thrust next-generation cause find successful biotechnology.

Read Entire Article